ChartMill assigns a Buy % Consensus number of 83% to NVCT. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-02 | Maxim Group | Initiate | Buy |
| 2025-03-17 | Laidlaw & Co. | Initiate | Buy |
| 2025-02-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-07 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-07-13 | Ladenburg Thalmann | Initiate | Buy |
| 2022-05-10 | HC Wainwright & Co. | Maintains | Buy |
| 2022-03-02 | HC Wainwright & Co. | Initiate | Buy |
12 analysts have analysed NVCT and the average price target is 18.53 USD. This implies a price increase of 119.03% is expected in the next year compared to the current price of 8.46.
The consensus rating for NUVECTIS PHARMA INC (NVCT) is 83.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.